Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Berichten met het trefwoord ‘Johnson & Johnson’

Bayer, J&J win second U.S. trial over Xarelto bleeding risks

A federal jury has cleared Bayer AG and Johnson & Johnson of liability in the second trial to stem from thousands of lawsuits blaming injuries on the blood thinner Xarelto, the drug companies said on Monday.

Bron: Reuters Meer lezen »

In the midst of a deadly opioid crisis, Ohio sues drugmakers for marketing fraud

After seeing drug overdoses become the state’s leading cause of accidental deaths, officials in Ohio have had enough. In a new lawsuit filed on Wednesday, Ohio’s attorney general is going after Teva, Allergan, Johnson & Johnson, Purdue and Endo for alleged “fraudulent marketing practices” on powerful opioid painkillers.

Bron: FiercePharma Meer lezen »

J&J fires off legal salvo to block Samsung’s Remicade biosim launch

Dead set on defending its top drug, Johnson & Johnson is taking South Korea’s Samsung Bioepis to federal court on claims the latter company is violating Remicade patents and refusing to participate in an established patent dispute resolution process.

Bron: FiercePharma Meer lezen »

FDA demands new warnings for J&J diabetes drug over amputation risk

Johnson & Johnson has found itself in deep water again over the potentially harmful effects of its products. This time it has found itself the target of FDA scrutiny, as the organisation is now requiring the company to add new precautionary labelling to its diabetes treatment Invokana (canagliflozin), warning users of the risk of foot […]

Bron: Pharmafile Meer lezen »

U.S. prosecutors zero in on J&J marketing, targeting top immunology, hep C meds

As if Johnson & Johnson didn’t have enough legal woes already, with the mounting number of cases claiming a link between its talcum powder and ovarian cancer, the pharma giant now faces a fresh round of investigations into its marketing practices.

Bron: FiercePharma Meer lezen »

J&J, Bayer face first jury trial over blockbuster Xarelto’s bleedings risks

The first federal trial over the bleeding risks of Xarelto, Johnson & Johnson and Bayer’s blockbuster anticoagulant, kicks off next week, with 18,000 more cases stacked up behind it. It will be the initial indicator of whether juries are likely to side with the drugmakers, ruling that their med is safe and effective, or patients, […]

Bron: FiercePharma Meer lezen »

J&J ordered to pay $5m over false marketing claims

Johnson & Johnson has become embroiled in yet another class-action lawsuit concerning its products; this time the company is accused of falsely claiming its baby bedtime bath products are “clinically proven” to aid sleep, despite no evidence to support this.

Bron: Meer lezen »

J&J and Bayer’s Xarelto cuts recurrence of dangerous blood clots in study

Longer-term use of the oral blood thinner Xarelto significantly cut the risk of recurrence of potentially life-threatening blood clots with no additional major bleeding compared with low-dose aspirin in patients at elevated risk, according to data presented on Saturday. Researchers said the results could change treatment of patients who have suffered dangerous blood clots known as […]

Bron: Reuters Meer lezen »

J&J taps the power of empathy with apps that take wellness beyond its products

Experience and expertise are important in business strategy, but a top Johnson & Johnson marketing exec believes another E-word needs to join that list—empathy. The healthcare giant’s consumer business plans to do just that, to differentiate its brands and drive beyond product messaging.

Bron: FiercePharma Meer lezen »

Johnson & Johnson completes acquisition of Abbott Medical Optics

Johnson & Johnson (NYSE: JNJ) has completed the acquisition of Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott. The all-cash $4.325 billion acquisition was originally announced Sept. 16, 2016, and includes ophthalmic products in three areas of patient care: cataract surgery, laser refractive surgery and consumer eye health.

Bron: World Pharma News Meer lezen »

« Oudere artikelen |